Aurobindo's Dyrupeg Biosimilar Secures UK Regulator's Approval

CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has received marketing authorization for its biosimilar Dyrupeg from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

The approval is an important milestone in Aurobindo Pharma's overarching growth and expansion strategy for biosimilars and a further endorsement of its increasingly strong position in the oncology support market segment.

Dyrupeg is a biosimilar to pegfilgrastim, a long-acting formulation of filgrastim used to prevent neutropenia (a potential life-threatening decrease in white blood cells) associated with chemotherapy. The approval by the UK regulator follows European Commission approval following a January 2025 positive Opinion from the Committee for Medicinal Products for Human Use (CHMP).

This is the third MHRA approved product for CuraTeQ Biologics, following approvals for Bevqolva (December 2024) and Zefylti (May 2025). The string of regulatory approvals demonstrates not only the R&D capabilities of the company but also the ability in reaching compliance and quality standards in biologics manufacture.

Also Read: Role of Optical Imaging in Early Cancer Detection and Treatment

Following the announcement, Aurobindo Pharma saw its shares gain 2.2% to close at ?1,119.90 on the BSE. The company continues to build momentum in the global biosimilars space, with Dyrupeg strengthening its portfolio of oncology-related therapies and contributing to more accessible treatment options for cancer patients worldwide.